PURPOSE: The cancer/germline antigen NY-ESO-1 is variably expressed in epithelial ovarian cancer (EOC), with most tumors showing low or heterogeneous expression, which limits patient responses to NY-ESO-1 vaccine therapy. We tested the hypothesis that promoter and global genomic DNA methylation status correlates with intertumor and intratumor NY-ESO-1 expression status in EOC. EXPERIMENTAL DESIGN: We utilized 78 EOC tumors and 10 normal ovary controls for quantitative DNA methylation analyses and NY-ESO-1 expression analysis by immunohistochemistry (IHC) and quantitative reverse transcriptase PCR. A subset of EOC tumors were used to perform microdissections of NY-ESO-1 IHC-positive and NY-ESO-1 IHC-negative tissue regions, followed by DNA methylation analyses. EOC cell lines were treated in vitro with decitabine to determine the functional contribution of DNA methylation to NY-ESO-1 gene regulation in EOC. RESULTS: Compared with normal ovary, bulk EOC tissues display increased NY-ESO-1 expression, reduced NY-ESO-1 promoter methylation, and reduced LINE-1 DNA methylation. However, NY-ESO-1 expression is not significantly associated with NY-ESO-1 promoter methylation status in bulk tumors. We hypothesized that this resulted from heterogeneous intratumor NY-ESO-1 expression. Supporting this idea, experiments using microdissected material revealed that intertumor and intratumor NY-ESO-1 expression heterogeneity is significantly correlated with promoter and global DNA methylation status in EOC. Moreover, decitabine treatment functionally restored NY-ESO-1 expression in nonexpressing EOC cell lines. CONCLUSION: DNA methylation status is associated with both intertumor and intratumor NY-ESO-1 expression status in EOC. These findings support a novel chemoimmunotherapy approach using decitabine to augment NY-ESO-1 vaccine therapy for treatment of recurrent EOC.
PURPOSE: The cancer/germline antigen NY-ESO-1 is variably expressed in epithelial ovarian cancer (EOC), with most tumors showing low or heterogeneous expression, which limits patient responses to NY-ESO-1 vaccine therapy. We tested the hypothesis that promoter and global genomic DNA methylation status correlates with intertumor and intratumor NY-ESO-1 expression status in EOC. EXPERIMENTAL DESIGN: We utilized 78 EOC tumors and 10 normal ovary controls for quantitative DNA methylation analyses and NY-ESO-1 expression analysis by immunohistochemistry (IHC) and quantitative reverse transcriptase PCR. A subset of EOC tumors were used to perform microdissections of NY-ESO-1 IHC-positive and NY-ESO-1 IHC-negative tissue regions, followed by DNA methylation analyses. EOC cell lines were treated in vitro with decitabine to determine the functional contribution of DNA methylation to NY-ESO-1 gene regulation in EOC. RESULTS: Compared with normal ovary, bulk EOC tissues display increased NY-ESO-1 expression, reduced NY-ESO-1 promoter methylation, and reduced LINE-1 DNA methylation. However, NY-ESO-1 expression is not significantly associated with NY-ESO-1 promoter methylation status in bulk tumors. We hypothesized that this resulted from heterogeneous intratumor NY-ESO-1 expression. Supporting this idea, experiments using microdissected material revealed that intertumor and intratumor NY-ESO-1 expression heterogeneity is significantly correlated with promoter and global DNA methylation status in EOC. Moreover, decitabine treatment functionally restored NY-ESO-1 expression in nonexpressing EOC cell lines. CONCLUSION: DNA methylation status is associated with both intertumor and intratumor NY-ESO-1 expression status in EOC. These findings support a novel chemoimmunotherapy approach using decitabine to augment NY-ESO-1 vaccine therapy for treatment of recurrent EOC.
Authors: Adam R Karpf; Amy W Lasek; Ted O Ririe; Adrianne N Hanks; Douglas Grossman; David A Jones Journal: Mol Pharmacol Date: 2004-01 Impact factor: 4.436
Authors: M L Gonzalgo; T Hayashida; C M Bender; M M Pao; Y C Tsai; F A Gonzales; H D Nguyen; T T Nguyen; P A Jones Journal: Cancer Res Date: 1998-03-15 Impact factor: 12.701
Authors: D J Smiraglia; L J Rush; M C Frühwald; Z Dai; W A Held; J F Costello; J C Lang; C Eng; B Li; F A Wright; M A Caligiuri; C Plass Journal: Hum Mol Genet Date: 2001-06-15 Impact factor: 6.150
Authors: Martin Widschwendter; Guanchao Jiang; Christian Woods; Hannes M Müller; Heidi Fiegl; Georg Goebel; Christian Marth; Elisabeth Müller-Holzner; Alain G Zeimet; Peter W Laird; Melanie Ehrlich Journal: Cancer Res Date: 2004-07-01 Impact factor: 12.701
Authors: Zhong-Zheng Zhu; Lifang Hou; Valentina Bollati; Letizia Tarantini; Barbara Marinelli; Laura Cantone; Allen S Yang; Pantel Vokonas; Jolanta Lissowska; Silvia Fustinoni; Angela C Pesatori; Matteo Bonzini; Pietro Apostoli; Giovanni Costa; Pier Alberto Bertazzi; Wong-Ho Chow; Joel Schwartz; Andrea Baccarelli Journal: Int J Epidemiol Date: 2010-09-15 Impact factor: 7.196
Authors: Ashok Sharma; Mustafa Albahrani; Wa Zhang; Christina N Kufel; Smitha R James; Kunle Odunsi; David Klinkebiel; Adam R Karpf Journal: Epigenetics Date: 2019-03-04 Impact factor: 4.528
Authors: Jessica A Hemminger; Amanda Ewart Toland; Thomas J Scharschmidt; Joel L Mayerson; Denis C Guttridge; O Hans Iwenofu Journal: Mod Pathol Date: 2014-01-24 Impact factor: 7.842
Authors: Pragya Srivastava; Benjamin E Paluch; Junko Matsuzaki; Smitha R James; Golda Collamat-Lai; Julia Karbach; Michael J Nemeth; Pietro Taverna; Adam R Karpf; Elizabeth A Griffiths Journal: Leuk Res Date: 2014-09-10 Impact factor: 3.156
Authors: Renee Vermeij; Toos Daemen; Geertruida H de Bock; Pauline de Graeff; Ninke Leffers; Annechien Lambeck; Klaske A ten Hoor; Harry Hollema; Ate G J van der Zee; Hans W Nijman Journal: Clin Dev Immunol Date: 2010-09-15
Authors: Ji-Yeob Choi; Smitha R James; Petra A Link; Susan E McCann; Chi-Chen Hong; Warren Davis; Mary K Nesline; Christine B Ambrosone; Adam R Karpf Journal: Carcinogenesis Date: 2009-07-07 Impact factor: 4.944